Loading
Loading
Metabolic & Body Composition · 20mg
Choose dose
Janoshik-tested · 10 vials per kit
Semaglutide is a long-acting GLP-1 receptor agonist studied in preclinical and clinical research for its metabolic and appetite-regulatory properties. Research has examined its potential to promote glucose-dependent insulin secretion, inhibit glucagon release, delay gastric emptying, and suppress appetite. Clinical data has associated its use with substantial weight reduction and improved cardiovascular outcomes, including a reduced risk of major adverse cardiovascular events in individuals with type 2 diabetes.
≥98%
Purity
Lyophilised
Format
2–3 wks
Arrival
Don't want to wait 3 weeks?
Check local stock — weekday same/next-day delivery available.
Chemical Properties
Need to work out your dose?
Use our reconstitution calculator — syringe units in seconds.
Research Use Only — Disclaimer
This product is intended solely as a research chemical for laboratory and scientific study purposes only. It is not approved by the TGA or any regulatory body for human or animal consumption, therapeutic use, or clinical application. The information provided on this website is for educational purposes only. Handling must be limited to suitably qualified professionals operating within applicable laws and regulations. This product is not classified as a drug, food, cosmetic, or medicinal product and must not be used or labelled as such. By purchasing, you confirm you are a qualified research professional and accept full responsibility for compliance with all relevant laws in your jurisdiction.
Semaglutide
Semaglutide is a long-acting synthetic analog of human glucagon-like peptide-1 (GLP-1), a 30-amino-acid incretin hormone secreted by intestinal L-cells in response to food intake. The molecule was engineered for an extended half-life of approximately 7 days through attachment of a C18 fatty diacid chain via a flexible linker to a modified lysine residue, enabling reversible albumin binding. It shares 94% sequence homology with native GLP-1.
Semaglutide binds GLP-1 receptors (GLP-1R) expressed on pancreatic beta cells, gut enterocytes, cardiac muscle, kidneys, and the central nervous system. In the pancreas it enhances glucose-dependent insulin secretion and suppresses glucagon release. In the hypothalamus and brainstem, GLP-1R activation reduces appetite and caloric intake. Peripheral receptor engagement slows gastric emptying, extending satiety. At the beta-cell level semaglutide also supports proliferation and protects against apoptosis.
Approved as Ozempic (weekly injection), Wegovy (obesity dosing), and Rybelsus (oral tablet), semaglutide has extensive human trial data from the SUSTAIN and STEP programmes demonstrating weight reduction, glycaemic improvement, and cardiovascular risk reduction. Active research areas include non-alcoholic fatty liver disease, heart failure, Alzheimer's disease (EVOKE trial), sleep apnoea, and chronic kidney disease.
Key References
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
Don't have supplies? Grab them while you're here.
